Press releases
Curium extends irradiation partnership with NRG | Pallas in Netherlands for continuous supply of Lutetium-177 to treat 1,000s of cancer patients each year
29th May 2024
Latest news, Events and Press Releases
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
Please direct any media inquiries to communications@curiumpharma.com
Press releases
Press releases
Curium announces first commercial doses in Germany of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
6th May 2024
Press releases
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
23rd April 2024
Press releases
Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol
8th April 2024
Press releases
Curium announces first commercial doses in the Netherlands of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
19th March 2024
Press releases
Curium announces first commercial doses in Italy of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
7th March 2024
Press releases
Curium announces submission of the marketing authorization application for PYLCLARI®, an innovative (18F)-PSMA PET tracer indicated in adults with prostate cancer to Swissmedic
21st February 2024
Press releases
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
6th February 2024
Press releases
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
21st November 2023
Press releases
Curium announces first patients in Europe injected with Pylclari® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
16th November 2023
Press releases
Curium and PIUR IMAGING announce thyroid imaging partnership in Germany to enable tomographic 3D ultrasound solutions
25th October 2023
Press releases
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
7th September 2023